Galmed Pharmaceuticals Ltd. has announced promising results from pre-clinical studies of their drug Aramchol, which shows significant anti-fibrotic effects in models of primary sclerosing cholangitis $(PSC.AU)$. Aramchol, an SCD1 inhibitor, demonstrated the ability to attenuate and prevent biliary fibrosis in mouse models of PSC, significantly inhibiting TGFβ-induced hepatic fibrosis pathways and upregulating PPAR signaling. These pre-clinical findings provide a strong rationale for further clinical trials, particularly in patients suffering from fibrosis-driven liver cancers. Galmed's President and CEO, Allen Baharaff, emphasized the potential for Aramchol to advance into Phase 2/3 clinical studies, given its robust anti-fibrotic effects previously observed in clinical studies with NASH and advanced fibrosis patients. This development marks a significant step forward in addressing the urgent need for effective treatments for biliary fibrosis and related liver conditions.